Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IB, Open-Label, Multicenter, Dose-Escalation Study Followed by an Extension Phase to Evaluate the Safety, Pharmacokinetics and Activity of RO5479599, a Glycoengineered Antibody Against HER3, Administered in Combination With Pertuzumab and Paclitaxel in Patients With Metastatic Breast Cancer Expressing HER3 & HER2 Protein

NCT01918254 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01918254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01918254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IB, Open-Label, Multicenter, Dose-Escalation Study Followed by an Extension Phase to Evaluate the Safety, Pharmacokinetics and Activity of RO5479599, a Glycoengineered Antibody Against HER3, Administered in Combination With Pertuzumab and Paclitaxel in Patients With Metastatic Breast Cancer Expressing HER3 & HER2 Protein
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
August 6, 2013
Completion date
October 7, 2016
Enrollment
66 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer